103 related articles for article (PubMed ID: 1284504)
1. Mycobacterial adherence and BCG treatment of superficial bladder cancer.
Schamhart DH; de Boer EC; Bevers RF; Kurth KH; Steerenberg PA
Prog Clin Biol Res; 1992; 378():75-80. PubMed ID: 1284504
[TBL] [Abstract][Full Text] [Related]
2. The effects of intravesical pretreatment with pentosan polysulfate on the bacillus Calmette-Guérin induced immune reaction of the guinea pig.
De Reijke TM; De Boer LC; Steerenberg PA; Vos PC; Kurth KH; Schamhart DH
J Urol; 1994 Mar; 151(3):746-9. PubMed ID: 7508528
[TBL] [Abstract][Full Text] [Related]
3. Interaction between bacteria and the lumenal bladder surface: modulation by pentosan polysulfate, an experimental and theoretical approach with clinical implication.
Schamhart DH; de Boer EC; Kurth KH
World J Urol; 1994; 12(1):27-37. PubMed ID: 7516779
[TBL] [Abstract][Full Text] [Related]
4. The fate of bacillus Calmette-Guerin after intravesical instillation.
Durek C; Richter E; Basteck A; Rüsch-Gerdes S; Gerdes J; Jocham D; Böhle A
J Urol; 2001 May; 165(5):1765-8. PubMed ID: 11342972
[TBL] [Abstract][Full Text] [Related]
5. Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig.
de Boer EC; Steerenberg PA; van der Meijden AP; van Klingeren B; de Jong WH; Debruyne FM; Ruitenberg EJ
Prog Clin Biol Res; 1992; 378():81-93. PubMed ID: 1301589
[TBL] [Abstract][Full Text] [Related]
6. Effect of local pentosan polysulphate pretreatment on the immune response to intravesical BCG.
de Boer EC; Schamhart DH; Vos PC; Vleeming R; Kurth KH
Investig Urol (Berl); 1994; 5():95-9. PubMed ID: 7536525
[No Abstract] [Full Text] [Related]
7. [Enhancement of bacillus Calmette-Guerin attachment to the bladder wall: experimental study].
Shen Z; Ding G; Chen Z
Zhonghua Wai Ke Za Zhi; 2001 Dec; 39(12):951-3. PubMed ID: 16201181
[TBL] [Abstract][Full Text] [Related]
8. Modulation of fibronectin-mediated Bacillus Calmette-Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways.
Hudson MA; Brown EJ; Ritchey JK; Ratliff TL
Cancer Res; 1991 Jul; 51(14):3726-32. PubMed ID: 2065329
[TBL] [Abstract][Full Text] [Related]
9. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
[TBL] [Abstract][Full Text] [Related]
10. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
Ratliff TL; Palmer JO; McGarr JA; Brown EJ
Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
[TBL] [Abstract][Full Text] [Related]
11. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
12. Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer.
Zlotta A; Drowart A; van Vooren JP; Simon J; Schulman CC; Huygen K
Acta Urol Belg; 1994 Sep; 62(3):63-8. PubMed ID: 7976857
[TBL] [Abstract][Full Text] [Related]
13. Effects of sequential intravesical administration of mitomycin C and bacillus Calmette-Guérin on the immune response in the guinea pig bladder.
Balemans LT; Vegt PD; Steerenberg PA; De Boer EC; Van Swaaij A; De Vries RE; Van der Meijden AP; Den Otter W
Urol Res; 1994; 22(4):239-45. PubMed ID: 7871637
[TBL] [Abstract][Full Text] [Related]
14. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
15. Intravesical and intradermal Bacillus Calmette-Guérin application. A phase I study to the toxicity of a Dutch Bacillus Calmette-Guérin preparation in patients with superficial bladder cancer.
Schreinemachers LM; van der Meijden AP; Wagenaar J; Steerenberg PA; Feitz WF; Groothuis DG; Tiesjema RH; de Jong WH; Debruyne FM; Ruitenberg EJ
Eur Urol; 1988; 14(1):15-21. PubMed ID: 2963745
[TBL] [Abstract][Full Text] [Related]
16. Intravesical BCG administration in the guinea pig. II. Immunohistochemical characterization of cellular infiltrate after one or two cycles of intravesical BCG.
de Jong WH; De Boer EC; Van Der Meijden AP; Steerenberg PA; Debruyne FM
Virchows Arch B Cell Pathol Incl Mol Pathol; 1991; 61(3):159-67. PubMed ID: 1685277
[TBL] [Abstract][Full Text] [Related]
17. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
Chang SG; Lee SJ; Huh JS; Lee JH
Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
[TBL] [Abstract][Full Text] [Related]
18. BCG-RIVM: a new BCG preparation for intravesical immunotherapy of superficial bladder cancer.
Schreinemachers L; Van der Meyden A; Steerenberg P; Feitz W; Groothuis D; De Jong W; Debruyne F
Chemioterapia; 1987 Jun; 6(2 Suppl):713-6. PubMed ID: 3334665
[No Abstract] [Full Text] [Related]
19. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
20. [Intravesical BCG therapy for superficial bladder cancer].
Segawa N; Iwamoto Y; Azuma H; Yamamoto K; Ueda H; Katsuoka Y
Hinyokika Kiyo; 1998 Sep; 44(9):627-31. PubMed ID: 9805666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
